Global Asia-Pacific Antibody-Drug Conjugates (Adc) Market - 2025-2033
Description
Asia-Pacific Antibody-Drug Conjugates (ADC) Market – Industry Trends & Outlook
The Asia-Pacific antibody-drug conjugates (ADC) market reached US$ 0.83 Billion in 2024 and is expected to reach US$ 2.11 Billion by 2033, growing at a CAGR of 12.4% during the forecast period of 2025-2033.
ADCs integrate the precision of monoclonal antibodies with the strength of cytotoxic drugs, enabling accurate targeting and treatment of tumors. This targeted delivery method improves therapeutic effectiveness and minimizes the systemic toxicity often linked to conventional chemotherapy. By attaching to particular antigens on cancer cells, ADCs promote the uptake of the cytotoxic agent, resulting in cell death while protecting healthy cells.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market Dynamics: Drivers
Increasing Cancer Incidence
The rising incidence of cancer is a significant driver for the Asia-Pacific antibody-drug conjugates market. As the number of cancer cases continues to grow, there is a growing need for more effective and targeted therapies, which ADCs can provide. This targeted therapy approach allows for greater efficacy and reduced toxicity compared to traditional chemotherapy, making ADCs an attractive option for both patients and healthcare providers.
For instance, in March 2025, Researchers at Concept to Medicine Biotech Co. Ltd., Lepu Biopharma Co. Ltd., and Shanghai Miracogen Inc. have developed a new class of antibody-drug conjugates (ADCs) that specifically target a protein called trophoblast glycoprotein (TPBG), also known as 5T4. These ADCs are designed to treat various types of cancer.
Additionally, advancements in antibody engineering and conjugation technologies are a significant factor in enhancing the market potential of antibody-drug conjugates. Significant progress has been made in antibody engineering and conjugation technologies, enabling the development of more potent and stable ADCs.
For instance, in February 2024, Daiichi Sankyo officially launched its subsidiary in Singapore as part of its strategic expansion to enhance the reach of its antibody-drug conjugates (ADCs) for cancer treatment. This initiative reflects the company's commitment to addressing unmet medical needs in oncology, particularly in a region where cancer accounts for nearly 30% of all deaths.
Rising research activities
Rising research activities are a fundamental driver accelerating the growth of the Asia-Pacific antibody-drug conjugate (ADC) market. This dynamic is reshaping the region’s oncology landscape and fueling innovation, investment, and market expansion.
The Asia-Pacific region is witnessing a significant increase in clinical research focused on ADCs, with numerous early-stage and late-stage trials underway in countries such as China, Japan, and South Korea. This surge is supported by both local and multinational pharmaceutical companies aiming to develop next-generation ADCs with improved efficacy and safety profiles. Increased R&D investment is leading to a robust pipeline of novel ADC candidates targeting a wide range of cancers, including breast, lung, and gastrointestinal malignancies.
For instance, in January 2025, Shanghai Henlius Biotech received approval from China’s National Medical Products Administration (NMPA) to begin a phase 1b/2 clinical trial of its novel PD-L1-targeting antibody-drug conjugate (ADC), HLX43, in combination with its innovative anti-PD-1 monoclonal antibody, serplulimab (HANSIZHUANG), for the treatment of advanced or metastatic solid tumors.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market Dynamics: Restraints
High manufacturing costs
High manufacturing costs are a significant barrier to the growth and accessibility of the Asia-Pacific ADC market. This restraint stems from the complex, resource-intensive nature of ADC development and production, and it has direct implications for patient access, market expansion, and the financial sustainability of healthcare systems.
ADCs are intricate molecules composed of a monoclonal antibody, a cytotoxic payload, and a chemical linker. Each component requires specialized synthesis and precise conjugation processes, demanding advanced facilities, highly skilled personnel, and rigorous quality control measures.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market Dynamics: Opportunities
Expansion of contract manufacturing and outsourcing
The expansion of contract manufacturing and outsourcing is a major opportunity propelling the Asia-Pacific antibody-drug conjugate (ADC) market. This trend is driven by the region’s cost advantages, regulatory support, skilled workforce, and increasing demand for advanced cancer therapies.
Asia-Pacific presents a powerful opportunity for the ADC market by offering cost-effective, high-quality, and scalable manufacturing solutions. This enables both local and global biopharma companies to accelerate ADC development, meet rising cancer treatment demand, and maintain a competitive edge in a rapidly growing market.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market - Segment Analysis
The Asia-Pacific antibody-drug conjugates (ADC) market is segmented based on product type, target type, technology type, application, and end-user.
Application:
The breast cancer application segment is expected to hold 39.3% of the Asia-Pacific antibody-drug conjugates (ADC) market in 2024
The breast cancer application segment is the leading and most commercially significant area within the global antibody-drug conjugate (ADC) market, accounting for nearly half of the market’s revenue share. This dominance is driven by the rising incidence of breast cancer worldwide and the remarkable success of ADCs as targeted therapies, particularly for HER2-positive and HER2-low subtypes.
Approved ADCs such as Kadcyla (ado-trastuzumab emtansine) and Enhertu (trastuzumab deruxtecan) have demonstrated superior efficacy and safety compared to conventional chemotherapy, as they deliver potent cytotoxic drugs directly to cancer cells while minimizing harm to healthy tissues.
The segment is further propelled by ongoing research, technological advancements in linker and payload design, and a robust pipeline of new ADC candidates. For instance, in November 2024, Sacituzumab tirumotecan, a next-generation antibody-drug conjugate (ADC) developed by Sichuan Kelun-Biotech, was approved by China’s National Medical Products Administration (NMPA) for the treatment of patients with unresectable, locally advanced, or metastatic triple-negative breast cancer (TNBC) who have previously received at least two systemic therapies.
Also, in January 2024, BioNTech and DualityBio initiated a pivotal Phase 3 clinical trial of their antibody-drug conjugate (ADC) candidate, BNT323/DB-1303, for the treatment of metastatic breast cancer. This ADC is specifically designed to target HER2, a protein expressed on the surface of certain breast cancer cells, including those with low levels of HER2 expression, a population with limited targeted treatment options.
Product type:
The Kadcyla product type segment is expected to hold 33.4% of the Asia-Pacific antibody-drug conjugates (ADC) market in 2024
Kadcyla (ado-trastuzumab emtansine) is an advanced antibody-drug conjugate (ADC) specifically designed for the treatment of HER2-positive breast cancer. It consists of the monoclonal antibody trastuzumab, which selectively binds to the HER2 receptor on cancer cells, covalently linked to the potent cytotoxic agent DM1 through a stable thioether (MCC) linker.
The mechanism of action involves Kadcyla binding to the HER2 receptor on the surface of cancer cells, after which the entire ADC-receptor complex is internalized into the cell via endocytosis. Once inside, Kadcyla is degraded in the lysosomes, releasing DM1 directly into the tumor cell. DM1 then binds to microtubules, inhibiting their polymerization, which leads to cell-cycle arrest and ultimately cell death—effectively delivering chemotherapy directly to HER2-overexpressing cancer cells while sparing most healthy tissues.
Kadcyla has been approved in multiple countries for the treatment of patients with advanced or metastatic HER2-positive breast cancer, particularly those who have previously received trastuzumab and chemotherapy. Its targeted approach has been shown to improve survival outcomes and reduce systemic toxicity compared to traditional chemotherapy, establishing Kadcyla as a standard of care and a benchmark product in the ADC market.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market – Competitive Landscape
The major players in the Asia-Pacific antibody-drug conjugates (ADC) market include Pfizer, Inc., AstraZeneca, GSK plc, DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., ADC Therapeutics, Astellas Pharma Inc., ImmunoGen, Inc., ACROBiosystems, and RemeGen Co., Ltd., among others.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market – Key Developments
• In May 2025, Astellas Pharma Inc. and Evopoint Biosciences entered into an exclusive license agreement for XNW27011, a novel clinical-stage antibody-drug conjugate (ADC) that targets CLDN18.2, a protein known as claudin 18.2. Under this agreement, Astellas has secured exclusive rights (outside of mainland China, Hong Kong, Macao, and Taiwan) to develop and commercialize XNW27011 globally.
• In January 2025, Innovent Biologics and Roche entered into an exclusive global license agreement for IBI3009, a novel antibody-drug conjugate (ADC) targeting DLL3, a protein highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors but minimally present in normal tissues.
• In June 2024, ArriVent BioPharma, a clinical-stage biopharmaceutical company focused on accelerating the development of innovative therapeutics, entered into a strategic collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a subsidiary of Alphamab Oncology. This partnership aims to discover, develop, and commercialize novel antibody-drug conjugates (ADCs) targeted at treating various cancers.
• In December 2024, Daiichi Sankyo is investing $152 million (1.1 billion Chinese yuan) to build a new antibody-drug conjugate (ADC) manufacturing facility in Shanghai, China, marking its first ADC plant in the country.
• In February 2024, Daiichi Sankyo launched its Singapore entity to expand the reach of its antibody-drug conjugates (ADCs) for people living with cancer. This move is part of the company’s broader strategy to address unmet needs in oncology and improve patient outcomes, particularly in Asia-Pacific, by leveraging Singapore’s status as a key scientific and innovation hub.
The Asia-Pacific antibody-drug conjugates (ADC) Market report delivers a detailed analysis with 51 key tables, more than 47 visually impactful figures, and 156 pages of expert insights, providing a complete view of the market landscape.
The Asia-Pacific antibody-drug conjugates (ADC) market reached US$ 0.83 Billion in 2024 and is expected to reach US$ 2.11 Billion by 2033, growing at a CAGR of 12.4% during the forecast period of 2025-2033.
ADCs integrate the precision of monoclonal antibodies with the strength of cytotoxic drugs, enabling accurate targeting and treatment of tumors. This targeted delivery method improves therapeutic effectiveness and minimizes the systemic toxicity often linked to conventional chemotherapy. By attaching to particular antigens on cancer cells, ADCs promote the uptake of the cytotoxic agent, resulting in cell death while protecting healthy cells.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market Dynamics: Drivers
Increasing Cancer Incidence
The rising incidence of cancer is a significant driver for the Asia-Pacific antibody-drug conjugates market. As the number of cancer cases continues to grow, there is a growing need for more effective and targeted therapies, which ADCs can provide. This targeted therapy approach allows for greater efficacy and reduced toxicity compared to traditional chemotherapy, making ADCs an attractive option for both patients and healthcare providers.
For instance, in March 2025, Researchers at Concept to Medicine Biotech Co. Ltd., Lepu Biopharma Co. Ltd., and Shanghai Miracogen Inc. have developed a new class of antibody-drug conjugates (ADCs) that specifically target a protein called trophoblast glycoprotein (TPBG), also known as 5T4. These ADCs are designed to treat various types of cancer.
Additionally, advancements in antibody engineering and conjugation technologies are a significant factor in enhancing the market potential of antibody-drug conjugates. Significant progress has been made in antibody engineering and conjugation technologies, enabling the development of more potent and stable ADCs.
For instance, in February 2024, Daiichi Sankyo officially launched its subsidiary in Singapore as part of its strategic expansion to enhance the reach of its antibody-drug conjugates (ADCs) for cancer treatment. This initiative reflects the company's commitment to addressing unmet medical needs in oncology, particularly in a region where cancer accounts for nearly 30% of all deaths.
Rising research activities
Rising research activities are a fundamental driver accelerating the growth of the Asia-Pacific antibody-drug conjugate (ADC) market. This dynamic is reshaping the region’s oncology landscape and fueling innovation, investment, and market expansion.
The Asia-Pacific region is witnessing a significant increase in clinical research focused on ADCs, with numerous early-stage and late-stage trials underway in countries such as China, Japan, and South Korea. This surge is supported by both local and multinational pharmaceutical companies aiming to develop next-generation ADCs with improved efficacy and safety profiles. Increased R&D investment is leading to a robust pipeline of novel ADC candidates targeting a wide range of cancers, including breast, lung, and gastrointestinal malignancies.
For instance, in January 2025, Shanghai Henlius Biotech received approval from China’s National Medical Products Administration (NMPA) to begin a phase 1b/2 clinical trial of its novel PD-L1-targeting antibody-drug conjugate (ADC), HLX43, in combination with its innovative anti-PD-1 monoclonal antibody, serplulimab (HANSIZHUANG), for the treatment of advanced or metastatic solid tumors.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market Dynamics: Restraints
High manufacturing costs
High manufacturing costs are a significant barrier to the growth and accessibility of the Asia-Pacific ADC market. This restraint stems from the complex, resource-intensive nature of ADC development and production, and it has direct implications for patient access, market expansion, and the financial sustainability of healthcare systems.
ADCs are intricate molecules composed of a monoclonal antibody, a cytotoxic payload, and a chemical linker. Each component requires specialized synthesis and precise conjugation processes, demanding advanced facilities, highly skilled personnel, and rigorous quality control measures.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market Dynamics: Opportunities
Expansion of contract manufacturing and outsourcing
The expansion of contract manufacturing and outsourcing is a major opportunity propelling the Asia-Pacific antibody-drug conjugate (ADC) market. This trend is driven by the region’s cost advantages, regulatory support, skilled workforce, and increasing demand for advanced cancer therapies.
Asia-Pacific presents a powerful opportunity for the ADC market by offering cost-effective, high-quality, and scalable manufacturing solutions. This enables both local and global biopharma companies to accelerate ADC development, meet rising cancer treatment demand, and maintain a competitive edge in a rapidly growing market.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market - Segment Analysis
The Asia-Pacific antibody-drug conjugates (ADC) market is segmented based on product type, target type, technology type, application, and end-user.
Application:
The breast cancer application segment is expected to hold 39.3% of the Asia-Pacific antibody-drug conjugates (ADC) market in 2024
The breast cancer application segment is the leading and most commercially significant area within the global antibody-drug conjugate (ADC) market, accounting for nearly half of the market’s revenue share. This dominance is driven by the rising incidence of breast cancer worldwide and the remarkable success of ADCs as targeted therapies, particularly for HER2-positive and HER2-low subtypes.
Approved ADCs such as Kadcyla (ado-trastuzumab emtansine) and Enhertu (trastuzumab deruxtecan) have demonstrated superior efficacy and safety compared to conventional chemotherapy, as they deliver potent cytotoxic drugs directly to cancer cells while minimizing harm to healthy tissues.
The segment is further propelled by ongoing research, technological advancements in linker and payload design, and a robust pipeline of new ADC candidates. For instance, in November 2024, Sacituzumab tirumotecan, a next-generation antibody-drug conjugate (ADC) developed by Sichuan Kelun-Biotech, was approved by China’s National Medical Products Administration (NMPA) for the treatment of patients with unresectable, locally advanced, or metastatic triple-negative breast cancer (TNBC) who have previously received at least two systemic therapies.
Also, in January 2024, BioNTech and DualityBio initiated a pivotal Phase 3 clinical trial of their antibody-drug conjugate (ADC) candidate, BNT323/DB-1303, for the treatment of metastatic breast cancer. This ADC is specifically designed to target HER2, a protein expressed on the surface of certain breast cancer cells, including those with low levels of HER2 expression, a population with limited targeted treatment options.
Product type:
The Kadcyla product type segment is expected to hold 33.4% of the Asia-Pacific antibody-drug conjugates (ADC) market in 2024
Kadcyla (ado-trastuzumab emtansine) is an advanced antibody-drug conjugate (ADC) specifically designed for the treatment of HER2-positive breast cancer. It consists of the monoclonal antibody trastuzumab, which selectively binds to the HER2 receptor on cancer cells, covalently linked to the potent cytotoxic agent DM1 through a stable thioether (MCC) linker.
The mechanism of action involves Kadcyla binding to the HER2 receptor on the surface of cancer cells, after which the entire ADC-receptor complex is internalized into the cell via endocytosis. Once inside, Kadcyla is degraded in the lysosomes, releasing DM1 directly into the tumor cell. DM1 then binds to microtubules, inhibiting their polymerization, which leads to cell-cycle arrest and ultimately cell death—effectively delivering chemotherapy directly to HER2-overexpressing cancer cells while sparing most healthy tissues.
Kadcyla has been approved in multiple countries for the treatment of patients with advanced or metastatic HER2-positive breast cancer, particularly those who have previously received trastuzumab and chemotherapy. Its targeted approach has been shown to improve survival outcomes and reduce systemic toxicity compared to traditional chemotherapy, establishing Kadcyla as a standard of care and a benchmark product in the ADC market.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market – Competitive Landscape
The major players in the Asia-Pacific antibody-drug conjugates (ADC) market include Pfizer, Inc., AstraZeneca, GSK plc, DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., ADC Therapeutics, Astellas Pharma Inc., ImmunoGen, Inc., ACROBiosystems, and RemeGen Co., Ltd., among others.
Asia-Pacific Antibody-Drug Conjugates (ADC) Market – Key Developments
• In May 2025, Astellas Pharma Inc. and Evopoint Biosciences entered into an exclusive license agreement for XNW27011, a novel clinical-stage antibody-drug conjugate (ADC) that targets CLDN18.2, a protein known as claudin 18.2. Under this agreement, Astellas has secured exclusive rights (outside of mainland China, Hong Kong, Macao, and Taiwan) to develop and commercialize XNW27011 globally.
• In January 2025, Innovent Biologics and Roche entered into an exclusive global license agreement for IBI3009, a novel antibody-drug conjugate (ADC) targeting DLL3, a protein highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors but minimally present in normal tissues.
• In June 2024, ArriVent BioPharma, a clinical-stage biopharmaceutical company focused on accelerating the development of innovative therapeutics, entered into a strategic collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a subsidiary of Alphamab Oncology. This partnership aims to discover, develop, and commercialize novel antibody-drug conjugates (ADCs) targeted at treating various cancers.
• In December 2024, Daiichi Sankyo is investing $152 million (1.1 billion Chinese yuan) to build a new antibody-drug conjugate (ADC) manufacturing facility in Shanghai, China, marking its first ADC plant in the country.
• In February 2024, Daiichi Sankyo launched its Singapore entity to expand the reach of its antibody-drug conjugates (ADCs) for people living with cancer. This move is part of the company’s broader strategy to address unmet needs in oncology and improve patient outcomes, particularly in Asia-Pacific, by leveraging Singapore’s status as a key scientific and innovation hub.
The Asia-Pacific antibody-drug conjugates (ADC) Market report delivers a detailed analysis with 51 key tables, more than 47 visually impactful figures, and 156 pages of expert insights, providing a complete view of the market landscape.
Table of Contents
180 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
